Study selection for primary analyses of outcomes of interest
Of the 59 studies identified by the systematic literature search, 22 were excluded as follows:
• 11 did not report results for any of the efficacy outcomes of interest
• 7 were of insufficient duration, i.e. ≤8 weeks
• 2 were excluded because of small study populations and lack of usable data
• 1 was a small-scale (N<10) exploratory study with undefined primary efficacy endpoint
• 1 was excluded as it was a Phase II study Further to the above, two replicate studies whose data was also reported in a pooled analysis were identified by the literature search. For simplicity and consistency, the pooled data were included in the analysis rather than the individual studies. Thirty six studies (including the pooled analysis) were therefore considered for inclusion in the three outcome analyses. Of these, 33 were included in at least one of the three main MTC analyses.
Change from baseline in FEV 1
Of the aforementioned 36 studies, 8 were excluded from the FEV 1 analysis because change from baseline in FEV 1 was not reported. Twenty eight studies were therefore included in the FEV 1 network.
Annual rate of moderate/severe exacerbations
Ten of the 36 studies were excluded from the exacerbations analysis because usable exacerbation data could not be extracted or calculated. Eleven studies were excluded from the main analysis because patients did not have a documented history of exacerbations, or exacerbation history data were not collected or reported. The exacerbation analysis therefore comprised data from 15 studies. Of the 11 studies that were excluded because of lack of explicit history of exacerbations prior to study start, six were examined in a sensitivity analysis of the exacerbations model in which the exacerbation history covariate was not considered.
